|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 25, 2017 ) Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume.
Publisher's analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021.
For more information about this report: http://www.reportsweb.com/global-critical-care-therapeutics-market-2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global critical care therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of critical care therapeutics was considered.
The market is divided into the following segments based on geography:
-Americas
-APAC
-EMEA
Publisher's report, Global Critical Care Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
-CSL Behring
-Grifols
-Kedrion Biopharma
-Octapharma
-Shire
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001572741/sample .
Other prominent vendors
-Abeona Therapeutics
-ADMA Biologics
-Albumedix
-Armetheon
-Asklepios BioPharmaceutical
-Aspen Pharma
-Baxter
-Bayer HealthCare
-Bio Products Laboratory
-BioDelivery Sciences
-Biogen Idec
-BioMarin
-Biotest Pharmaceuticals
-Bristol-Myers Squibb
-Catalyst Biosciences
-China Biologic Products
-Cosmo Pharmaceuticals
-Kamada
-King Pharmaceuticals
-Medxbio
-Merck
-Mitsubishi Tanabe Pharma
-Novo Nordisk
-Novozymes
-Portola Pharmaceuticals
-ProMetic Life Sciences
-rEVO Biologics
-Rockwell Medical
-Sanquin
-Shanghai RAAS
-Teva Pharmaceutical
-The Medicines Company
-Thermo Fisher Scientific
-Tianjin SinoBiotech & Beijing Bio-Fortune
-Ventria Bioscience
Market driver
-Growing preference for marketed products over alternative treatment options.
-For a full, detailed list, view our report
Market challenge
-Existence of plasma fractionation supply and demand gap.
-For a full, detailed list, view our report
Market trend
-Increased development of recombinant products for critical care use.
-For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001572741/buying .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
